NIAID to Grant Exclusive Patent License for Zika Vaccine to PaxVax

Summary

The National Institute of Allergy and Infectious Diseases (NIAID) is considering granting an exclusive patent license to PaxVax, Inc. to commercialize a DNA-based vaccine for the prevention of Zika virus infection, as outlined in a recent notice.